Browse Category

Investment News News 9 December 2025

Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Published: December 9, 2025 Arcellx, Inc. (NASDAQ: ACLX) has jumped back onto Wall Street’s radar after releasing highly positive Phase 2 data for its multiple myeloma cell therapy anitocabtagene autoleucel (“anito-cel”) at the American Society of Hematology (ASH) 2025 meeting.
Confluent (CFLT) Stock Surges on IBM’s $11 Billion Takeover – What the $31 Cash Offer Means for Investors on December 9, 2025

Confluent (CFLT) Stock Surges on IBM’s $11 Billion Takeover – What the $31 Cash Offer Means for Investors on December 9, 2025

Updated: December 9, 2025 Key takeaways Important: This article is for information and news purposes only and is not investment advice. Confluent stock today: trading near the IBM offer As of mid‑day on December 9, 2025, Confluent, Inc. (NASDAQ: CFLT)
Netflix Stock Falls as Warner Bros. Deal Faces Hostile Challenge – What NFLX Investors Need to Know Now

Netflix Stock Falls as Warner Bros. Deal Faces Hostile Challenge – What NFLX Investors Need to Know Now

Netflix, Inc. (NASDAQ: NFLX) stock is under pressure again on December 9, 2025, as Wall Street digests a rare combination of events: a giant, high‑risk media acquisition, a surprise hostile counterbid, fresh analyst downgrades, and a rapidly scaling ads business
Astera Labs (ALAB) Stock Jumps on AI Optimism: Latest News, Analyst Price Targets and Forecasts for December 9, 2025

Astera Labs (ALAB) Stock Jumps on AI Optimism: Latest News, Analyst Price Targets and Forecasts for December 9, 2025

Astera Labs, Inc. (NASDAQ: ALAB) is back in the spotlight on Tuesday, December 9, 2025, as the AI‑infrastructure specialist rallies and fresh analyst commentary and institutional filings reshape the narrative around one of the market’s most closely watched semiconductor IPOs.
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about
1 24 25 26 27 28 71
Go toTop